Skip to main content
GutCited
Figure 8

Descripción

Correlation analysis between gut microbial abundance and lysophosphatidic acid levels identifies specific bacterial species linked to metabolite production. Berberine's microbiome modulation appears to reduce cancer-promoting metabolites.

More Figures from This Paper

16S rRNA sequencing of gut microbiota reveals that berberine modulates microbial community composition in high-fat diet-fed mice. Specific bacterial genera associated with colorectal cancer risk were reduced in berberine-treated animals.

Figure 3

16S rRNA sequencing of gut microbiota reveals that berberine modulates microbial community composition in high-fat diet-fed mice. Specific bacterial genera associated with colorectal cancer risk were reduced in berberine-treated animals.

chart
Lysophosphatidic acid signaling pathway components are quantified in colonic tissue. Berberine treatment is associated with downregulation of key enzymes in this pathway, suggesting a mechanism for its anti-tumor effects.

Figure 4

Lysophosphatidic acid signaling pathway components are quantified in colonic tissue. Berberine treatment is associated with downregulation of key enzymes in this pathway, suggesting a mechanism for its anti-tumor effects.

chart
Metabolomic profiling of gut contents identifies lysophosphatidic acid and related lipid metabolites altered by berberine supplementation. Reduced levels of pro-tumorigenic lipids correlate with tumor suppression.

Figure 5

Metabolomic profiling of gut contents identifies lysophosphatidic acid and related lipid metabolites altered by berberine supplementation. Reduced levels of pro-tumorigenic lipids correlate with tumor suppression.

chart
Western blot analysis demonstrates changes in protein expression of key signaling molecules in the lysophosphatidic acid pathway following berberine treatment. Reduced phosphorylation of downstream targets indicates pathway inhibition.

Figure 6

Western blot analysis demonstrates changes in protein expression of key signaling molecules in the lysophosphatidic acid pathway following berberine treatment. Reduced phosphorylation of downstream targets indicates pathway inhibition.

chart
Fecal microbiota transplantation experiments confirm the role of gut microbiota in mediating berberine's anti-tumor effects. Mice receiving microbiota from berberine-treated donors showed reduced tumor development.

Figure 7

Fecal microbiota transplantation experiments confirm the role of gut microbiota in mediating berberine's anti-tumor effects. Mice receiving microbiota from berberine-treated donors showed reduced tumor development.

chart
Immune cell infiltration in colonic tumors is assessed across treatment groups. Berberine supplementation is associated with increased anti-tumor immune responses and reduced immunosuppressive cell populations.

Figure 9

Immune cell infiltration in colonic tumors is assessed across treatment groups. Berberine supplementation is associated with increased anti-tumor immune responses and reduced immunosuppressive cell populations.

chart

Figure 8

Chart
989 × 1261px · 340,6 KB

Source Paper

Berberine inhibits high fat diet-associated colorectal cancer through modulation of the gut microbiota-mediated lysophosphatidylcholine.

International journal of biological sciences (2023)

PMID: 37151876

DOI: 10.7150/ijbs.81824

Cite This Figure

![Figure 8: Correlation analysis between gut microbial abundance and lysophosphatidic acid levels identifies specific bacterial species linked to metabolite production. Berberine's microbiome modulation appears to reduce cancer-promoting metabolites.](https://pdfs.citedhealth.com/figures/37151876/208.png)

> Source: Haitao Chen et al. "Berberine inhibits high fat diet-associated colorectal cancer through modulation." *International journal of biological sciences*, 2023. PMID: [37151876](https://pubmed.ncbi.nlm.nih.gov/37151876/)
<figure>
  <img src="https://pdfs.citedhealth.com/figures/37151876/208.png" alt="Correlation analysis between gut microbial abundance and lysophosphatidic acid levels identifies specific bacterial species linked to metabolite production. Berberine's microbiome modulation appears to reduce cancer-promoting metabolites." />
  <figcaption>Figure 8. Correlation analysis between gut microbial abundance and lysophosphatidic acid levels identifies specific bacterial species linked to metabolite production. Berberine's microbiome modulation appears to reduce cancer-promoting metabolites.<br>  Source: Haitao Chen et al. "Berberine inhibits high fat diet-associated colorectal cancer through modulation." <em>International journal of biological sciences</em>, 2023. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37151876/">37151876</a></figcaption>
</figure>

Evidencia relacionada

D
Berberine para Gut Dysbiosis

Calificación D · 2 estudios